Clinical Trials Logo

FSGS clinical trials

View clinical trials related to FSGS.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT02399462 Withdrawn - Clinical trials for Kidney Transplantation

Acthar for Treatment of Post-transplant FSGS

Start date: March 2021
Phase: Phase 4
Study type: Interventional

This is an open label safety and feasibility trial using Acthar® in addition to center-specific standard therapy including plasma exchange, for treatment of post transplant recurrent FSGS and post transplant recurrent idiopathic membranous nephropathy. Subjects will receive Acthar® 40 units subcutaneously (SC) twice weekly for two weeks then 80 units SC twice weekly for 24 weeks.